PetVivo Holdings (PetVivo Holdings) Growth Rank : 0 (As of May. 21, 2024)

View and export this data going back to 2012. Start your Free Trial

What is PetVivo Holdings Growth Rank?

PetVivo Holdings has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

PetVivo Holdings Growth Rank Related Terms

Thank you for viewing the detailed overview of PetVivo Holdings's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

PetVivo Holdings (PetVivo Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » PetVivo Holdings Inc (OTCPK:PETV) » Definitions » Growth Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

5251 Edina Industrial Boulevard, Edina, MN, USA, 55439

Website

https://www.petvivo.com

PetVivo Holdings Inc is an emerging biomedical device company. The group is focused on the manufacturing, commercialization, and licensing of medical devices and therapeutics for companion animals. A key strategy of the company is to leverage human therapies for the treatment of companion animals cost-effectively and in a timely manner. The accelerated timeline to revenues for veterinary medical devices is a key component of this strategy, which enter the market much earlier than pharmaceuticals and biologics. The product pipeline includes approximately seventeen products intended to treat animals and people. Its patent protection extends to biomaterials, products, production processes, and methods of use provided by the company's portfolio of nineteen patents.

Executives

James Rudolph Martin	director	POBOX 53988, IRVINE CA 92619
A.l. Sarroff Fund, Llc	10 percent owner	43 MEADOW WOODS ROAD, GREAT NECK NY 11020
John Spencer Breithaupt	director	3041 W. PASADENA DR., BOISE ID 83705
Robert J Costantino	director	5805 SEPULVEDA BLVD., SUITE 801, SHERMAN OAKS CA 91411
Joseph William Jasper	director	201 SOUTH 11TH STREET, UNIT 1030, MINNEAPOLIS MN 55403
John Lai	director, 10 percent owner, officer: CEO	12100 SINGLETREE LANE, SUITE 186, EDEN PRAIRIE MN 55344
Robert James Rudelius	director	6913 ARBOR LANE, MCCLEAN VA 22101
Leslie Anne Coolidge	director	345 OLD SUTTON ROAD, BARRINGTON HILLS IL 60010
Robert J. Folkes	officer: Chief Financial Officer	1331 TYLER STREET NE, SUITE 200, MINNEAPOLIS MN 55413
Scott Mitchell Johnson	director	475 LAKESHORE UNIT #32, INCLINE VILLAGE NV 89451
James Joseph Martin	director	4400 BISCAYNE BLVD, SUITE # 670, MIAMI FL 33157
Gregory D Cash	director
John Michael Carruth	officer: Acting Chief Financial Officer	4923 RIVER WOOD DR., SAVAGE MN 55439
Sherry Grisewood	director	377 FAIRMOUNT ROAD, CALIFON NJ 07830
David Don Deming	director	16200 45TH STREET SOUTH, AFTON MN 55001